* |
BRAVECTO kills fleas and prevents flea infestations for 12 weeks. BRAVECTO Chew and BRAVECTO Topical Solution for Dogs kill ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kill lone star ticks for 8 weeks. BRAVECTO Topical Solution for Cats kills ticks (black-legged tick) for 12 weeks and American dog ticks for 8 weeks. |
1BRAVECTO Chew [prescribing information], Madison, NJ: Merck Animal Health; 2014.
2BRAVECTO Topical Solution for Dogs [prescribing information], Madison, NJ: Merck Animal Health; 2016.
3BRAVECTO Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal Health; 2016.
4Taenzler et al. Parasites & Vectors. 2014;7:567. |
Important Safety Information:
BRAVECTO has not been shown to be effective for 12-weeks’ duration in puppies or kittens less than 6 months of age. BRAVECTO Chew: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. BRAVECTO is not effective against lone star ticks beyond 8 weeks of dosing. BRAVECTO Topical Solution for Dogs: The most common adverse reactions recorded in clinical trials were vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. BRAVECTO is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Use caution in dogs with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. BRAVECTO Topical Solution for Cats: The most common adverse reactions recorded in clinical trials were vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of BRAVECTO has not been established in breeding, pregnant and lactating cats. Use with caution in cats with a history of neurologic abnormalities. Neurologic abnormalities have been reported in cats receiving BRAVECTO, even in cats without a history of neurologic abnormalities.
View prescribing information:
BRAVECTO Chew | BRAVECTO Topical Solution for Dogs | BRAVECTO Topical Solution for Cats
Copyright © 2018 Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc. All rights reserved.
If you no longer wish to receive these emails from Merck Animal Health, please unsubscribe here.
Merck Animal Health is committed to protecting your privacy. Information on the collection and use of your personal information may be viewed at www.merck.com/privacy.
This email was sent on behalf of Intervet Inc., Madison, NJ 07940 USA. US/BRV/0318/0063a |